Cooperative Agreement U44AA026126

This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to utilize the recipient's DNA-encoded library (DEL) drug discovery platform to identify therapeutic compounds targeting the orphan receptor GPR37 for treating amphetamine use disorders. The $398,093 award to Jillion Therapeutics Inc., a Brooklyn-based biotechnology company, will fund a 1-year project to produce and purify the GPR37 receptor, screen a...

This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...

Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,483 to Jillion Therapeutics Inc. to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for the treatment of substance use disorders (SUDs). The key objectives are to: 1) Screen a DEL of 125 million compounds plus an additional 1 million GPCR-focused compounds...

This Cooperative Agreement award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $999,393 to Stress Therapeutics, Inc. to initiate investigational new drug (IND)-enabling studies for a novel first-in-class therapeutic candidate aimed at the chronic management of pathological hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of alcohol use disorder (AUD). The key activities funded under...

This federal Project Grant award of $731,258, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) grant program, supports a 12-week multicenter clinical trial to examine the efficacy of guanfacine extended release (GXR) versus placebo in reducing drinking severity in women with alcohol use disorder (AUD). The study aims to target alcohol craving and emotion regulation during stress as potential mechanisms. It will use a...

This $223,531 Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a Phase Ia/b proof-of-concept study to evaluate the use of the FDA-approved drug diclofenac as a potential novel treatment for alcohol use disorder (AUD). The study will be conducted by the University of Maryland, Baltimore and aims to determine the optimal dosage of diclofenac that increases levels of the neuroprotective metabolite...

The National Institute on Drug Abuse (NIDA) awarded a $634,048 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a human laboratory study on advancing troriluzole as a treatment for methamphetamine use disorder (MUD). The study aims to evaluate the effects of troriluzole, a glutamate-modulating compound, on the reinforcing and abuse-related effects of methamphetamine in people with MUD alone and those...

This $366,406 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Yale University. The grant will be used to develop two novel human laboratory models to screen potential medications for Alcohol Use Disorder (AUD). The first model will assess a medication's ability to increase abstinence and reduce heavy drinking, which align with key FDA endpoints for AUD medication approval. The second model will...